Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2004-09-01 Regulatory Filings
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings
2004-09-01 English
FORM 10-QSB (06/30/04)
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-QSB filed with the U.S. Securities and Exchange Commission, indicating it is a quarterly report. It contains detailed unaudited interim consolidated financial statements, management's discussion and analysis, notes to the financial statements, and other financial information for the quarter ended June 30, 2004. The presence of financial statements and substantive financial data confirms it is a comprehensive interim report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2004-08-16 English
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2004-06-28 English
PRIMARY DOCUMENT
Director's Dealing
2004-05-27 English
FORM 10-QSB 03-31-04
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-QSB filed with the U.S. Securities and Exchange Commission for the quarterly period ended March 31, 2004. It contains interim consolidated financial statements, management's discussion and analysis, notes to the financial statements, and other quarterly report information. The presence of unaudited interim financial statements and detailed financial data for a period shorter than a full fiscal year confirms this is a quarterly report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2004-05-20 English
FORM 12B-25
Regulatory Filings Classification · 95% confidence The document is a Form 12B-25 filed with the SEC, which is a Notification of Late Filing. It specifically indicates that the company, Genemax Corp., is notifying the SEC that it could not file its quarterly report on Form 10-QSB for the quarter ended March 31, 2004 within the prescribed period. The document explains the reasons for the delay and provides some narrative on anticipated financial results, but it does not contain the actual quarterly report or substantive financial statements. The document is a regulatory notification about the delay in filing a quarterly report rather than the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such notifications and certifications.
2004-05-17 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.